Next Article in Journal
B-Cell Acute Lymphoblastic Leukemia as a Secondary Malignancy Following Diffuse Large B-Cell Lymphoma
Previous Article in Journal
Availability of All-Trans Retinoic Acid and Support Systems for Management of Acute Promyelocytic Leukemia in Michigan and Louisiana, USA
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 11
Issue 2
10.4081/hr.2019.7826
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Implications of Intrachromosomal Amplification of Chromosome 21 on Outcome in Pediatric Acute Lymphoblastic Leukemia: Does It Affect Our Patients Too?

by
Suleimman Al-Sweedan
1,* and
Rahaf Altahan
2
1
Department of Pediatrics, Jordan University of Science and Technology, Irbid 22110, Jordan
2
Hematology Unit, Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh 11564, Saudi Arabia
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2019, 11(2), 7826; https://doi.org/10.4081/hr.2019.7826
Submission received: 18 February 2018 / Revised: 13 February 2019 / Accepted: 25 March 2019 / Published: 14 June 2019

Abstract

Intrachromosomal amplification (iAMP) of chromosome 21 entity is associated with a dismal outcome in B cell Acute Lymphoblastic Leukemia (B-ALL). This cytogenetic abnormality is caused by a novel mechanism; breakage-fusion-bridge cycles followed by chromothripsis along with major gross rearrangements in chromosome 21.Charts of B-ALL diagnosed at King Faisal Specialist Hospital and Research Center between 2005 and 2015 were reviewed.iAMP is a rare entity occurring at around 2.4% of all pediatrics B-ALL. No statistically significant difference was found among patients with iAMP21, patients with extra copies of 21 and other patients with B-ALL. The reported adverse prognostic effect of iAMP21 could be due to other coexistent adverse factors, including older age at the time of diagnosis. The most common associated abnormality in our population in addition to the hyperdiploidy was ETV6/RUNX1.
Keywords: B-cell acute lymphoblastic leukemia; intrachromosomal amplification of chromosome 21; outcome B-cell acute lymphoblastic leukemia; intrachromosomal amplification of chromosome 21; outcome

Share and Cite

MDPI and ACS Style

Al-Sweedan, S.; Altahan, R. Implications of Intrachromosomal Amplification of Chromosome 21 on Outcome in Pediatric Acute Lymphoblastic Leukemia: Does It Affect Our Patients Too? Hematol. Rep. 2019, 11, 7826. https://doi.org/10.4081/hr.2019.7826

AMA Style

Al-Sweedan S, Altahan R. Implications of Intrachromosomal Amplification of Chromosome 21 on Outcome in Pediatric Acute Lymphoblastic Leukemia: Does It Affect Our Patients Too? Hematology Reports. 2019; 11(2):7826. https://doi.org/10.4081/hr.2019.7826

Chicago/Turabian Style

Al-Sweedan, Suleimman, and Rahaf Altahan. 2019. "Implications of Intrachromosomal Amplification of Chromosome 21 on Outcome in Pediatric Acute Lymphoblastic Leukemia: Does It Affect Our Patients Too?" Hematology Reports 11, no. 2: 7826. https://doi.org/10.4081/hr.2019.7826

APA Style

Al-Sweedan, S., & Altahan, R. (2019). Implications of Intrachromosomal Amplification of Chromosome 21 on Outcome in Pediatric Acute Lymphoblastic Leukemia: Does It Affect Our Patients Too? Hematology Reports, 11(2), 7826. https://doi.org/10.4081/hr.2019.7826

Article Metrics

Back to TopTop